Who won: Ono type DX Breast Recurrence Score Test

About this contract

Oncotype DX is a clinically validated multigene assay for predicting the likely benefit of chemotherapy in this patient population and is uniquely available from the current supplier on the global market.

Who won contracts like this

• ✓Answer against the marking scheme, not the question text — Leeds Teaching Hospitals NHS Trust scores each response, so map your evidence to the published criteria and weightings.
• ✓At £337,500, expect quality and social value to carry a large share of the score — price alone rarely wins goods work.
• ✓Show recent, comparable delivery: name similar goods contracts you've delivered for public bodies, with measurable outcomes.
• ✓This one's been awarded — but Leeds Teaching Hospitals NHS Trust retenders on a cycle. Get matched the day the next one lands and start your draft early.

BidWriter drafts your responses from your company profile, scores them against the marking scheme, and tracks your whole pipeline. Free to start — no card needed.

Related resources

Similar contracts